However, several systematic reviews conducted by the American College of Gastroenterology Task Force showed poor quality of evidence that particular antispasmodics and antidiarrheals can reduce defecation frequency but that they cannot affect the overall symptoms of IBS; 5-HT3 agonists carry a possible risk of ischemic colitis and cardiovascular events [1]. Here, HTR3A is linked to ischemic colitis.